NEW TEST – Available Now

Click for Pricing

Rapid Acute Myeloid Leukemia Targeted Therapy Mutation Panel

3017050, RAPID AML

Specimen Requirements:	
Patient Preparation:	
Collect:	Lavender (whole blood or bone marrow collected in EDTA), green (peripheral blood or bone marrow collected in sodium heparin)
Specimen Preparation:	Whole Blood or Bone Marrow: Transport 2 mL (Min: 1.0 mL)
Transport Temperature:	Whole Blood or Bone Marrow: Refrigerated.
Unacceptable Conditions:	Serum, plasma, grossly hemolyzed specimens, buccal brush or swab, FFPE tissue, or frozen samples.
Remarks:	
Stability:	Whole blood: Ambient: 1 week, Refrigerated: 2 weeks, Frozen: Unacceptable Bone marrow: Ambient: 72 hours, Refrigerated: 1 week, Frozen: Unacceptable
Methodology:	Massively Parallel Sequencing
Performed:	Varies
Reported:	3-7 days
Note:	The following regions are targeted to detect clinically relevant hotspot mutations, unless otherwise indicated: CEBPA* (NM_004364) exon 1; FLT3 (NM_004119) exons 14, 15, 16, 20; IDH1 (NM_005896) exon 4; IDH2 (NM_002168) exon 4; KIT (NM_000222) exons 8, 9, 10, 11, 17; KRAS (NM_004985) exons 2, 3, 4; NPM1 (NM_002520) exon 11; NRAS (NM_002524) exons 2, 3, 4; TP53*(NM_000546) all coding exons *CEBPA and TP53 are fully covered; any clinically relevant or potentially relevant variants will be reported. More information about the targeted regions of this test is included in the Additional Technical Information.
CPT Codes:	81450
New York DOH Approval Status:	Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.

Interpretive Data:
Refer to report.
Reference Interval:

HOTLINE NOTE: Refer to the Hotline Test Mix for interface build information.